Targeted therapies for specific forms (e.g., APOL1-mediated FSGS)

Type: drug

Status: Investigational

Developer: Vertex Pharmaceuticals

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026